3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Interventions
Paclitaxel
337
pembrolizumab
332
Carboplatin
329
Cisplatin
276
Gemcitabine
264
Docetaxel
251
Bevacizumab
239
Nivolumab
230
Pemetrexed
210
Rituximab
183
Dexamethasone
183
Cyclophosphamide
169
Capecitabine
169
Trastuzumab
149
Fluorouracil
147
Ipilimumab
121
atezolizumab
118
Prednisone
117
Erlotinib Hydrochloride
116
Oxaliplatin
109
Cetuximab
104
Sunitinib
101
Leucovorin
97
Doxorubicin
97
Lenalidomide
93
Irinotecan
89
130-nm albumin-bound paclitaxel
84
durvalumab
77
Bortezomib
77
Azacitidine
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has results
×
fedratinib
×
Clear all
NCT03952039
2025-08-28
FREEDOM2
Celgene
Phase 3
Completed
202 enrolled
23 charts
NCT03755518
2024-12-12
FREEDOM
Celgene
Phase 3
Terminated
38 enrolled
23 charts